“Sofosbuvir plus Daclatasvir without Ribavirin for the Treatment of Chronic Hepatitis C in Patients with Decompensated Liver Disease: Response of sofosbuvir plus daclatasvir in decompensated cirrhosis” (2020) Journal of Fatima Jinnah Medical University, 14(1), pp. 41–44. doi:10.37018/WOXS1774.